Neurocrine Biosciences (NASDAQ:NBIX) Expands Portfolio with $2.9 Billion Soleno Therapeutics Acquisition

Font: Financial Modeling Prep  • Apr 06, 2026

• Oppenheimer sets a bullish price target of $220 for NASDAQ:NBIX, indicating a potential upside of 66.06% from the current price.
• Neurocrine acquires Soleno Therapeutics for $2.9 billion in an all-cash deal, strengthening its position in endocrinology and rare diseases.
• The acquisition brings VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, into Neurocrine's portfolio, supporting long-term revenue growth.

Neurocrine Biosciences (NASDAQ:NBIX) is a leading biopharmaceutical company focused on developing treatments for neurological and endocrine-related disorders. Its portfolio includes notable products like INGREZZA and CRENESSITY. Recently, Oppenheimer set a price target of $220 for NBIX, suggesting a potential increase of approximately 66.06% from its current price of $132.48.

In a strategic move, Neurocrine announced its acquisition of Soleno Therapeutics for $2.9 billion. This all-cash deal values Soleno at $53 per share, offering a 34% premium over its recent closing price. The acquisition aims to bolster Neurocrine's presence in the endocrinology and rare disease sectors.

The acquisition focuses on Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, a condition affecting around 10,000 people in the U.S. The addition of VYKAT XR is expected to enhance Neurocrine's commercial portfolio and drive long-term revenue growth.

Following the acquisition announcement, Soleno's shares surged over 32% to approximately $52. However, Neurocrine's stock saw a slight decrease of 2%, settling at $129. This reflects market reactions to the acquisition's potential impact on Neurocrine's financials.

Neurocrine's acquisition strategy is supported by a strong intellectual property estate for VYKAT XR, projected to last into the mid-2040s. This move is expected to create a durable platform for growth, aligning with Oppenheimer's optimistic price target for NBIX.